A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)

Cohort 1 and 2: Number of EGFR ex20ins Positive Participants With Cytology or Histology at the Time of NGS Testing

Number of EGFR ex20ins positive participants with adenocarcinoma, squamous cell carcinoma, mixed, or other carcinomas will be evaluated.

Time frame: Up to 3 years prior to leading site initiation

Cohort 1 and 2: Site of Metastasis at the Time of NGS Testing

Site of metastasis at the time of NGS testing will be reported.

Time frame: Up to 3 years prior to leading site initiation

Cohort 1 and 2: Number and Kinds of Co-occurring Mutations of EGFR ex20ins at Baseline in Positive Participants Detected by NGS Testing

The number and kinds of co-occurring mutations at baseline will be reported. The baseline is defined as treatment naive before NGS testing.

Time frame: Baseline (prior to NGS testing)

Cohort 2: Number of EGFR ex20ins Positive Participants, Participants With Common EGFR Mutations and Participants With EGFR Wild Type With Demographic Characteristics

Demographic characteristics include age, gender, smoking history and family history for malignancies.

Time frame: Up to 3 years prior to leading site initiation

Cohort 2: Number of EGFR ex20ins Positive Participants, Participants With Common EGFR Mutations and Participants With EGFR Wild Type With Clinical Stages of Lung Cancer at the Time of NGS Testing

Number of EGFR ex20ins positive participants, participants with common EGFR mutations and participants with EGFR wild type with the clinical stages of cancer IIIB, IIIC, IV will be evaluated using the international association for the study of lung cancer eighth edition of the TNM classification for staging criteria.

Time frame: Up to 3 years prior to leading site initiation

Cohort 2: Number of EGFR ex20ins Positive Participants, Participants With Common EGFR Mutations and Participants With EGFR Wild Type With Cytology or Histology at the Time of NGS Testing

Number of EGFR ex20ins positive participants, participants with common EGFR mutations and participants with EGFR wild type with adenocarcinoma, squamous cell carcinoma, mixed, or other carcinomas will be evaluated.

Time frame: Up to 3 years prior to leading site initiation

Cohort 2: Site of Metastasis at the Time of NGS Testing

Site of metastasis at the time of NGS testing will be reported.

Time frame: Up to 3 years prior to leading site initiation

Cohort 2: Number and Kinds of Co-occurring Mutations at Baseline in EGFR ex20ins Positive Participants, Participants With Common EGFR Mutations and Participants With EGFR Wild Type Detected by NGS Testing

The number and kinds of co-occurring mutations at baseline will be reported. The baseline is defined as treatment naive before NGS testing.

Time frame: Baseline (prior to NGS testing)